C. Yurdaydin Et Al. , "Entecavir (ETV) results in continued virologic and biochemical improvement through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)," LIVER INTERNATIONAL , vol.26, pp.14, 2006
Yurdaydin, C. Et Al. 2006. Entecavir (ETV) results in continued virologic and biochemical improvement through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026). LIVER INTERNATIONAL , vol.26 , 14.
Yurdaydin, C., Sollano, J., Hadziyannis, S., Kaymakoglu, S., Sherman, M., Brett-Smith, H., ... Vaughan, J.(2006). Entecavir (ETV) results in continued virologic and biochemical improvement through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026). LIVER INTERNATIONAL , vol.26, 14.
Yurdaydin, C. Et Al. "Entecavir (ETV) results in continued virologic and biochemical improvement through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)," LIVER INTERNATIONAL , vol.26, 14, 2006
Yurdaydin, C. Et Al. "Entecavir (ETV) results in continued virologic and biochemical improvement through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)." LIVER INTERNATIONAL , vol.26, pp.14, 2006
Yurdaydin, C. Et Al. (2006) . "Entecavir (ETV) results in continued virologic and biochemical improvement through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)." LIVER INTERNATIONAL , vol.26, p.14.
@article{article, author={C. Yurdaydin Et Al. }, title={Entecavir (ETV) results in continued virologic and biochemical improvement through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)}, journal={LIVER INTERNATIONAL}, year=2006, pages={14} }